Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2024-03-27 Capital/Financing Update
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Nyrada Commences Key Brain Injury Program Preclinical Study 3 pages 312.0KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 28 March 2024 from Nyrada Inc providing an update on its Brain Injury Program, including commencement of Good Laboratory Practice (GLP) safety testing studies, plans for a Phase I clinical trial, and a capital raise completed in March 2024. The content focuses on operational updates, preclinical and clinical study progress, and financing status. There are no detailed financial statements, comprehensive financial analysis, or full report disclosures typical of Annual Reports (10-K), Interim Reports (IR), or Earnings Releases (ER). The document is not a transcript, audit report, or governance-related filing. It is an update on capital raising and program progress, which fits best under Capital/Financing Update (CAP). The document length (6317 characters) and detailed content support it being a substantive update rather than a brief announcement or regulatory filing. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2024-03-27 English
Amended and Restated Certificate of Incorporation and Bylaw 30 pages 10.9MB
Regulatory Filings
2024-03-14 English
Application for quotation of securities - NYR 6 pages 18.5KB
Share Issue/Capital Change Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the securities to be quoted, their issue date, issue price, and the issued capital following quotation. It references previous announcements (Appendix 3B) related to the securities issuance. The document is a regulatory announcement related to capital market activities, specifically the quotation of securities, but it is not a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the securities and their quotation. This type of document fits best under the category of Share Issue/Capital Change (SHA), as it relates to the issuance and quotation of new securities.
2024-03-14 English
Cleansing Statement 2 pages 221.7KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Cleansing Statement' and references an Appendix 2A lodged on the same date. It discusses the issuance of CHESS Depositary Interests (CDIs) as part of a Capital Raising Program and compliance with sections of the Corporations Act 2001 (Cth). The document is short (3370 characters) and primarily serves as a regulatory notice about the issuance of securities without disclosure under certain provisions, confirming compliance with disclosure obligations. There are no financial statements, detailed financial data, or management discussion of results. The content aligns with announcements related to capital raising and compliance notices rather than full financial reports or earnings releases. Given the nature of the content and the reference to a capital raising program, the document fits best under Capital/Financing Update (CAP).
2024-03-14 English
Notice of Change of Interests of Substantial Securityholder 2 pages 234.6KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and shareholdings of substantial holders in Nyrada Inc. It includes specific data on the number of shares/CDIs held before and after the change, and the percentage voting power. There is no financial performance data, management discussion, or report content. The document is a notification of changes in significant share ownership levels, which fits the definition of 'Major Shareholding Notification' (MRQ). The document length is 3836 characters, which is consistent with a notification rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2024-03-14 English
Notice of Change of Interests of Substantial Securityholder 2 pages 231.0KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and holdings of a substantial shareholder (Noxopharm Limited) in Nyrada Inc. It includes specific numbers of shares/CDIs held before and after the change, along with voting power percentages. The document is relatively short (3526 characters) and focuses solely on the notification of a change in substantial shareholding. There is no financial data, management discussion, or report content. This matches the definition of a 'Major Shareholding Notification' (MRQ), which is a notification of changes in significant share ownership levels crossing thresholds. Therefore, the correct classification is MRQ with high confidence.
2024-03-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.